Navigation Links
Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer

roof of the principle for the therapeutic application of targeted ADVEXIN therapy in tumors with p53 abnormalities that are among the most common and fundamental molecular defects in cancer," said Neil Senzer, M.D., Scientific Director, Mary Crowley Medical Research Center, and lead author of the article. "ADVEXIN's mechanism of action is targeted to restoring p53 tumor suppressor function that is abnormal in Li-Fraumeni tumors and in many other types of cancer."

ADVEXIN is being developed for European markets by Gendux AB, a subsidiary of Introgen Therapeutics, Inc. The European Medicines Agency (EMEA) has designated, and the European Union has confirmed, ADVEXIN p53 therapy as an Orphan Drug for the treatment of LFS. A Letter of Intent to the EMEA regarding Marketing Authorization Application for the approval of ADVEXIN to treat LFS was filed under the Exceptional Circumstances Approval procedures in the EU.

Collaborators on this publication included clinicians from Mary Crowley Medical Research Center, Sammons Cancer Center, Baylor University Medical Center, The Royal Marsden Hospital NHS Foundation Trust, Imperial College London Hammersmith Campus, and the Institute of Cancer Research in the United Kingdom.

About Li-Fraumeni Syndrome

Approximately 400 families are affected by LFS annually. The majority of LFS families contain mutations in the p53 tumor suppressor gene. Affected individuals often develop multiple primary tumors, which typically occur at a young age. Conventional therapy of patients with the Li-Fraumeni Syndrome is frequently unsuccessful due to the occurrence of multiple malignancies that share a common p53 genetic defect fundamental to cancer progression and the development of treatment resistance. Defects in p53-mediated cell death pathways cause these tumors to develop resistance to standard therapy, resulting in early death. Additionally, because affected individuals lack p53-mediated DNA repair function, treatment
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
2. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
(Date:3/2/2015)...   Oriel STAT A MATRIX announces ... most critical compliance and performance issues in the ... are experiencing an industry-transforming level of demand and ... global supply chains are negatively impacting product quality ... regulators are increasing compliance requirements, scrutiny, and enforcement. ...
(Date:3/2/2015)... 2, 2015  Akron Children,s Hospital has been designated ... American College of Radiology (ACR), making it the first ... second children,s hospital in the United States ... "Earning recognition from the ACR as a DICOE provides ... level compared with national benchmarks," says Dr. Michael ...
(Date:3/2/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... proven cancer therapies in new orphan drug indications, ... Allowance from the U.S. Patent and Trademark Office ... Compositions and methods to improve the therapeutic benefit ...
Breaking Medicine Technology:Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 2Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 3Akron Children's designated ACR Diagnostic Imaging Center of Excellence 2DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 2DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 3DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 4
... NEW YORK, March 21, 2011 The Alzheimer,s Drug ... grant of $170,750 to ADispell Inc. to develop small ... loss that occurs with Alzheimer,s Disease. ... licensed technology from Cornell University to develop neuroprotective drug ...
... LLC , ( www.curemark.com ), a drug research and development ... the company has completed its targeted enrollment of Phase III ... Curemark has reached its targeted enrollment for the study ... CM-AT Phase III trial at 18 sites across the country. ...
Cached Medicine Technology:Alzheimer's Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimer's Disease 2Curemark Completes Enrollment of Phase III Autism Trials 2
(Date:3/2/2015)... NY (PRWEB) March 02, 2015 ... Administration (FDA) warned against the use of power ... and fibroid removal surgeries, insurer UnitedHealthCare is poised ... use of those devices. In a notification sent ... beginning in April, it would require pre-authorization for ...
(Date:3/2/2015)... New York (PRWEB) March 02, 2015 ... of Idoll Magazine, a medium for the model agency ... can find, and buy Mango, Passion Fruit, Pink Grapefruit, ... March 3rd, 2015, after 1pm. , At a cost ... has recently came under fire by announcing the brands ...
(Date:3/2/2015)... Gummy smile reduction expert, Dr. Alex ... involve one or several procedures to reduce the appearance of ... a more even gum line. Dr. Farnoosh is the creator ... can permanently lighten discolored or naturally dark gums. , ... personalized treatment plan to address a patient’s specific needs based ...
(Date:3/2/2015)... Minnetonka, MN (PRWEB) March 02, 2015 ... accredited temperature calibration for Secondary Standard Platinum ... (RTDs) in 5 business days or less . ... is NVLAP ® Accredited (Lab Code 200706-0), ... NIST traceability. Temperature range is -196°C to ...
(Date:3/2/2015)... Over the last five years the ultrasound market ... expand their geographic presence and achieve economies of scale. ... billion by 2019 at CAGR of 5.1% from 2014 ... Canada and a major part of Europe are mature ... Asia-Pacific including China and India, Latin America and the ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 4Health News:Sex Sells! A Newly Minted Organic Bodycare Brand Courts Controversy at a Cost 2Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3
... a company developing breakthrough molecular imaging agents ... announced today that the United States Patent ... 7,438,891, covering methods of imaging cardiovascular plaque ... patent, exclusively licensed from the Massachusetts General ...
... Increased 2% and Increased 1% Excluding the Impact of Foreign ... Decreased 7% and Decreased 1% Excluding the Impact of Foreign ... Increase Led by Growth in Excess of 10% for Prevnar, ... Jan. 26 Wyeth (NYSE: WYE ) today ...
... Saint Joseph,s Health System announced,that it has launched ... a,non-profit training center for robotic surgical teams from around ... Thoracic Surgeons (STS) annual,meeting in San Francisco. , ... to patients from robotic-assisted,surgery since we began our program ...
... To Stay Happy and Healthy This WinterSAN JOSE, Calif., ... avoiding the "winter blues" is to set small goals, ... and exercising, for a well-rounded approach to life. This ... Day of the Year," January 26, 2009, designated by ...
... Jan. 26 Concentric Medical, Inc., the global leader ... today announced that the company,s Merci Retrieval System(TM) has ... in August 2004. The Merci Retrieval System is ... to remove blood clots from patients suffering an ischemic ...
... Internal Manufacturing Scale-Up Underway to Support Increased Product ... (OTC Bulletin Board: BLFS), a leading developer and ... media products for cells, tissues, and organs, today ... full year 2008 and also the receipt of ...
Cached Medicine News:Health News:FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG 2Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 2Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 3Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 4Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 5Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 6Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 7Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 8Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 9Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 10Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 11Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 12Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 13Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 14Health News:Saint Joseph's Launches International College of Robotic Surgery 2Health News:Natural Solutions for the Most Depressing Day of the Year 2Health News:Natural Solutions for the Most Depressing Day of the Year 3Health News:Natural Solutions for the Most Depressing Day of the Year 4Health News:Natural Solutions for the Most Depressing Day of the Year 5Health News:Concentric Medical Reaches Important Stroke Milestone 2Health News:Concentric Medical Reaches Important Stroke Milestone 3Health News:BioLife Solutions Announces Record Revenue and Receipt of Funding 2Health News:BioLife Solutions Announces Record Revenue and Receipt of Funding 3
Provides maximum comfort upon insertion through ultra-smooth catheter eyelets--formed with advanced ultrasonic technology....
... cost-effective method of providing patient warming while ... warming tube is ideal for use in ... Radiology. The CSZ Warming Tube is the ... it may be used in almost any ...
... Our patient warming system consists of ... a range of blankets for use ... all clinical applications. Blankets are available ... adult and paediatric sizes and a ...
... is the automated benchtop solution for nucleic ... extensive integrated features and a sample throughput ... the system meets the demanding nucleic acid ... to medium sample throughput., ,The high-quality nucleic ...
Medicine Products: